Clinical trials: Leukaemia (Acute Myeloid)
Acute Lymphoblastic Leukaemia, Acute Myeloid Leukaemia
Study of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression
The purpose of this study is to understand the safety, tolerability, efficacy, pharmacokinetic (PK), pharmacodynamic (PD), and preliminary efficacy of orally administered AZD3632 in participants with advanced haematologic…
- Conditions
- Acute Lymphoblastic Leukaemia, Acute Myeloid Leukaemia, Higher-risk Myelodysplastic Syndromes
- Trial name
- MOMENTUM (NCT07155226)
- Testing
- AZD3632, Posaconazole
- Where
- 30 sites in United States, Australia and 7 more
- Volunteers
- 85 people
- Sponsor
- AstraZeneca
Acute Myeloid Leukaemia, High Risk Myelodysplastic Syndrome
Phase 1 Open-label Study of AMX-883 Alone in Participants With AML and High-risk MDS and in Combination in Participants With AML
The purpose of the study is to assess the safety, pharmacokinetics, and preliminary efficacy of AMX-883 monotherapy in participants with acute myeloid leukaemia (AML) and high-risk myelodysplastic syndrome (MDS) and in…
- Trial name
- BRAMLIE (NCT07723703)
- Testing
- AMX-883, Posaconazole
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- Amphista Therapeutics Ltd
Acute Myeloid Leukaemia (AML), Follicular Lymphoma ( FL)
A Longitudinal Multi-Center Molecular Biomarker Discovery Registry for Patients With Hematologic Malignancies
The TEMPUS AQUARIUS Study is a non-interventional, longitudinal observational study focused on hematological malignancies. It will collect rich molecular (multi-omic) and clinical data from patient cohorts through serial blood…
- Trial name
- Aquarius (NCT07154823)
- Testing
- None - Observational Study
- Where
- 13 sites in United States
- Volunteers
- 550 people
- Sponsor
- Tempus AI
Advanced Solid Tumors, Acute Myeloid Leukaemia (AML)
RVU120 Rollover Study
This is a multicenter rollover study to provide continued treatment to eligible participants previously enrolled in a RVU120 clinical study and to evaluate the safety of the treatment and record the time on treatment when…
- Conditions
- Advanced Solid Tumors, Acute Myeloid Leukaemia (AML), High-risk Myelodysplastic Syndrome
- Trial name
- ROVER-01 (NCT06987058)
- Testing
- RVU120, Ruxolitinib
- Where
- 7 sites in France, Poland
- Volunteers
- 14 people
- Sponsor
- Ryvu Therapeutics SA
Acute Myeloid Leukaemia (AML), Acute Myeloid Leukaemia
A Study to Assess How Well the Study Medicine IPN60340 Works in Combination With Azacitidine and Venetoclax, Compared to Placebo in Combination With Azacitidine and Venetoclax, in Participants With Newly Diagnosed Acute Myeloid Leukemia Who Cannot Receive Intensive Chemotherapy
The purpose of this study is to find out how well the study drug IPN60340 works to treat participants with acute myeloid leukemia. Acute myeloid leukemia is a rare blood cancer that grows quickly.
- Trial name
- EVICTION 3 (NCT07623187)
- Testing
- IPN60340 + azacitidine + venetoclax
- Volunteers
- 540 people
- Sponsor
- Ipsen
Acute Myeloid Leukaemia (AML)
L-Annamycin for Injection in Combination With Cytarabine Injection as Second Line Therapy for Remission Induction in Adult Subjects With Refractory/Relapsed AML
This pivotal phase 2/3, multi-center, adaptive design study of L-Annamycin for Injection in combination with Cytarabine Injection as second line therapy for remission induction in adult subjects with refractory/relapsed AML is…
- Trial name
- NCT06788756
- Testing
- Liposomal Annamycin Injection in combination with Cytarabine Injection, Liposomal Annamycin for Injection in combination with Cytarabine Injection.
- Where
- 28 sites in United States, Czechia and 7 more
- Volunteers
- 312 people
- Sponsor
- Moleculin Biotech, Inc.
Acute Lymphocytic Leukaemia, Acute Myeloid Leukaemia Refractory
First-in-human Study of SAR443579 Infusion in Male and Female Children and Adult Participants With Relapsed or Refractory Acute Myeloid Leukemia (R/R AML), B-cell Acute Lymphoblastic Leukemia (B-ALL), High Risk-myelodysplasia (HR-MDS), or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
This is an open-label, multicenter, Phase 1/Phase 2, dose escalation and dose expansion study to evaluate the safety, pharmacokinetics, pharmacodynamics and anti-leukemic activity of SAR443579 in various hematological…
- Conditions
- Acute Lymphocytic Leukaemia, Acute Myeloid Leukaemia Refractory, Myelodysplastic Syndromes, Blastic Plasmacytoid Dendritic Cell Neoplasia
- Trial name
- NCT05086315
- Testing
- SAR443579
- Where
- 23 sites in United States, Australia and 3 more
- Volunteers
- 101 people
- Sponsor
- Sanofi
Acute Myeloid Leukaemia
A Study to Investigate Use of Off-the-shelf Natural Killer (NK) Cells (SAR445419) in Relapsed/Refractory Acute Myeloid Leukemia
This is a single group, Phase 1, single-arm, dose escalation study to determine the candidate dose(s), and evaluate safety, tolerability, and preliminary anti-tumor activity of SAR445419 administered after fludarabine and…
- Trial name
- NCT05712278
- Testing
- SAR445419, fludarabine, cytarabine
- Where
- 3 sites in United States
- Volunteers
- 7 people
- Sponsor
- Sanofi
Acute Myeloid Leukaemia (AML), Myelodysplastic Syndrome (MDS)
Effect of Moderate Renal Impairment and Race/Ethnicity on Treosulfan Pharmacokinetics
This study aim is to assess, if treosulfan pharmacokinetics are influenced by declined renal function and by race/ethnicity of patients.
- Conditions
- Acute Myeloid Leukaemia (AML), Myelodysplastic Syndrome (MDS), Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)
- Trial name
- NCT05534620
- Testing
- Treosulfan, Fludarabine
- Where
- 3 sites in United States
- Volunteers
- 20 people
- Sponsor
- medac GmbH
Relapsed/Refractory Acute Myeloid Leukaemia, Myeloid Malignancy
Study of Lisaftoclax (APG-2575) Single Agent and Combination With Therapy in Patients Relapsed/Refractory AML
The purpose of this study is to assess the safety, pharmacokinetic profile of Lisaftoclax (APG-2575) single agent and in combination with HHT/AZA in patients with relapsed/refractory AML and related myeloid malignancies.
- Trial name
- NCT04501120
- Testing
- Lisaftoclax (APG-2575), Reduced-dose HHT, standard-dose HHT
- Where
- 12 sites in China
- Volunteers
- 682 people
- Sponsor
- Ascentage Pharma Group Inc.
Acute Myeloblastic Leukaemia, Leukemia, T-Cell
Safety and Efficacy of GYA01 (CART84) in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) and Acute Lymphoblastic T Leukemia Patients (T-ALL).
This Phase I/IIa clinical study is testing an experimental treatment called GYA01 (CART84) for people with acute myeloid leukemia (AML) or T-cell acute lymphoblastic leukemia (T-ALL) whose disease has come back after treatment…
- Trial name
- NCT07471789
- Testing
- CART84
- Where
- 2 sites in Spain
- Volunteers
- 33 people
- Sponsor
- Gyala Therapeutics
ALL, Adult, AML, Adult
A Study of BN104 in the Treatment of Acute Leukemia
The Phase I/II trial is to learn the safety, pharmacokinetics, and preliminary efficacy of BN104 taken once daily or twice daily in patients with acute lymphocytic leukemia or acute myeloblastic leukemia.
- Conditions
- ALL, Adult, AML, Adult, Acute Leukaemia, KMT2A Rearrangement
- Trial name
- NCT06052813
- Testing
- BN104 monotherapy, BN104 monotherapy - rp2d
- Where
- China
- Volunteers
- 66 people
- Sponsor
- Institut de Recherches Internationales Servier (I.R.I.S.)
Acute Myeloid Leukaemia
Bioequivalence of Azacitidine 300 mg Film-Coated Tablets in Adult Patients With Acute Myeloid Leukaemia (AML)
A Randomized, Single Oral Dose, Open Label, Two Treatment, Crossover study to investigate the bioequivalence of the Test Product Azacitidine 300 mg Film coated tablets relative to Reference Product Onureg® 300 mg Film Coated…
- Trial name
- NCT06326697
- Testing
- Azacitidine, Onureg
- Where
- Saudi Arabia
- Volunteers
- 32 people
- Sponsor
- Hikma Pharmaceuticals LLC
Acute Myeloid Leukaemia
Clinical Study of U32 in Patients With Acute Myeloid Leukemia
This is a single-arm, open-label clinical study to evaluate the safety, tolerability, and efficacy of U32 injection in patients with acute myeloid leukemia.
- Trial name
- NCT07036250
- Testing
- U32 CAR-T
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd
Acute Myeloid Leukaemia
Safety, Tolerability, Pharmacokinetics, and Efficacy of AZD2811 Nanoparticles as Monotherapy or in Combination in Acute Myeloid Leukemia Participants.
This is a Phase I/II clinical study to determine the maximum tolerated dose (MTD), and schedule, safety, tolerability, pharmacokinetics, and pharmacodynamics of AZD2811 monotherapy or with combination agent(s) in…
- Trial name
- NCT03217838
- Testing
- AZD2811, Azacitidine, Venetoclax
- Where
- 11 sites in United States, Australia
- Volunteers
- 50 people
- Sponsor
- AstraZeneca
Acute Myeloid Leukaemia
Phase I Study of UCART123 in Patient With Adverse Genetic Risk Acute Myeloid Leukemia
This is a Phase I, open-label, dose escalation study of UCART123 administered intravenously to patients with newly diagnosed CD123 positive adverse genetic risk acute myeloid leukaemia (AML) defined in the ELN adverse genetic…
- Trial name
- NCT04106076
- Testing
- UCART123
- Sponsor
- Cellectis S.A.
Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukaemias (AML)
Treosulfan-based Conditioning in Paediatric Patients With Haematological Malignancies
The primary goal of this study is to evaluate an alternative myeloablative, but reduced toxicity conditioning regimen in children, to describe the safety and efficacy of intravenous (i.v.) Treosulfan administered as part of a…
- Conditions
- Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukaemias (AML), Myelodysplastic Syndromes (MDS), Juvenile Myelomonocytic Leukaemias (JMML)
- Trial name
- NCT02333058
- Testing
- Treosulfan
- Where
- 24 sites in Austria, Czechia and 4 more
- Volunteers
- 70 people
- Sponsor
- medac GmbH
Acute Myeloid Leukaemia Recurrent
The Effects of AMPC in the Treatments of Refractory or Relapsed AML
A private trial for evaluating the overall response rate contributed by AMPC in AML in refractory or relapsed AML
- Trial name
- AMPCAL (NCT03825146)
- Testing
- Autologous Multi-lineage Potential Cells (AMPC)
- Where
- Thailand
- Volunteers
- 10 people
- Sponsor
- Lai Corporation Pty. Ltd.
Acute Leukaemia
A Safety and Efficacy Study of Eltrombopag in Subjects With AML
The purpose of this randomized, blinded, placebo-controlled study was to provide clinical safety and exploratory efficacy data on the use of Eltrombopag in adult subjects with Acute Myeloid Leukemia (AML) receiving standard…
- Trial name
- NCT01890746
- Testing
- Daunorubicin, Cytarabine, Eltrombopag
- Where
- 42 sites in United States, Australia and 8 more
- Volunteers
- 148 people
- Sponsor
- Novartis Pharmaceuticals
Leukaemia, Myelocytic, Acute
A Phase I Dose Escalation Study of GSK2879552 in Subjects With Acute Myeloid Leukemia (AML)
This study is a phase I, open-label study to determine recommended phase 2 dose (RP2D) and regimen for the orally administered lysine specific demethylase 1 (LSD1) inhibitor GSK2879552, alone or in combination with All-Trans…
- Trial name
- NCT02177812
- Testing
- GSK2879552, ATRA
- Where
- 8 sites in United States, Australia and 1 more
- Volunteers
- 41 people
- Sponsor
- GlaxoSmithKline